Aptose Biosciences’ (APTO) Buy Rating Reiterated at HC Wainwright

Aptose Biosciences (NASDAQ:APTO) (TSE:APS)‘s stock had its “buy” rating restated by HC Wainwright in a research report issued on Wednesday,Benzinga reports. They presently have a $2.00 price target on the biotechnology company’s stock.

Separately, StockNews.com initiated coverage on Aptose Biosciences in a research report on Sunday. They set a “hold” rating for the company.

Aptose Biosciences Stock Up 22.9 %

Shares of Aptose Biosciences stock traded up $0.04 during trading on Wednesday, reaching $0.22. 100,876,374 shares of the company were exchanged, compared to its average volume of 4,190,982. The business has a 50-day moving average price of $0.21 and a 200-day moving average price of $0.32. The firm has a market capitalization of $13.32 million, a price-to-earnings ratio of -0.07 and a beta of 0.88. Aptose Biosciences has a twelve month low of $0.13 and a twelve month high of $2.12.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Aptose Biosciences stock. Sigma Planning Corp lifted its holdings in shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) by 71.3% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 401,750 shares of the biotechnology company’s stock after purchasing an additional 167,282 shares during the quarter. Sigma Planning Corp owned 2.22% of Aptose Biosciences worth $165,000 at the end of the most recent quarter. 26.62% of the stock is owned by institutional investors.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.